Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer

Journal of Cancer

Volumn 9, Issue 14, 2018, Pages 2510-2517

  Wu, Xinqiang ^a   Wu, Yuanbing ^b   He, Liangmei ^a   Wu, Longhuo ^a   Wang, Xiangcai ^a   Liu, Zhiping ^a,c  

^a GANNAN MEDICAL UNIVERSITY   (China)

^b The First People's Hospital of Jiashan County   (China)

^c Ganzhou Cancer Precision Engineering Research Center   (China)

Author keywords

Butyrate; Colorectal cancer; Diet; Gut microbiota

Indexed keywords

BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROPILIN; PROTEIN BAX; TRANSCRIPTION FACTOR SP1; WNT PROTEIN;

ANGIOGENESIS; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; DIET; DOWN REGULATION; GENE EXPRESSION; HUMAN; INTESTINE FLORA; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

EID: 85049220523     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.25324     Document Type: Review

References (93)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC CancerBase No. International Journal of Cancer. 2010; 136: E359-E86
2. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ (Clinical research ed). 2011; 343: d6617
3. Tuan J, Chen YX. Dietary and Lifestyle Factors Associated with Colorectal Cancer Risk and Interactions with Microbiota: Fiber, Red or Processed Meat and Alcoholic Drinks. Gastrointestinal Tumors. 2016; 3: 17-24
4. Cho M, Carter J, Harari S, Pei Z. The Interrelationships of the Gut Microbiome and Inflammation in Colorectal Carcinogenesis. Clinics in Laboratory Medicine. 2014; 34: 699-710
5. Arthur JC, Jobin C. The Struggle Within: Microbial Influences on Colorectal Cancer. Inflammatory Bowel Diseases. 2011; 17: 396-409
6. Kuwahara A. Contributions of colonic short-chain Fatty Acid receptors in energy homeostasis. Frontiers in Endocrinology. 2014; 5: 144
7. Macfarlane GT, Englyst HN. Starch utilization by the human large intestinal microflora. Journal of Applied Bacteriology. 1986; 60: 195-201
8. Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology. 1982; 83: 424-9
9. Le Marchand L, Kolonel LN. [Cancer in Japanese migrants to Hawaii: interaction between genes and environment]. Revue d'epidemiologie et de sante publique. 1992; 40: 425-30
10. Deng Y. Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence? Current Treatment Options in Oncology. 2017; 18: 64
11. Ferguson LR, Harris PJ. The dietary fibre debate: more food for thought. Lancet. 2003; 361: 1487-8
12. von Martels JZH, Sadaghian Sadabad M, Bourgonje AR, Blokzijl T, Dijkstra G, Faber KN, et al. The role of gut microbiota in health and disease: In vitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe. 2017; 44: 3-12
13. Shen TD. Diet and Gut Microbiota in Health and Disease. Nestle Nutrition Institute workshop series. 2017; 88: 117-26
14. Holscher HD. Dietary Fiber and Prebiotics and the Gastrointestinal Microbiota. Gut Microbes. 2017; 8: 172-84
15. Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, et al. Faecalibacterium prausnitzii and human intestinal health. Current Opinion in Microbiology. 2013; 16: 255-61
16. Duncan SH, Barcenilla A, Stewart CS, Pryde SE, Flint HJ. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Applied and Environmental Microbiology. 2002; 68: 5186-90
17. Zhu Q, Jin Z, Wu W, Gao R, Guo B, Gao Z, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PloS one. 2014; 9: e90849
18. Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, et al. Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients. Microbial Ecology. 2013; 66: 462-70
19. Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. Journal of Gastroenterology. 2015; 50: 167-79
20. Moore WE, Moore LH. Intestinal floras of populations that have a high risk of colon cancer. Applied and Environmental Microbiology. 1995; 61: 3202-7
21. Kostic A, Chun E, Robertson L, Glickman J, Gallini CA, Michaud M, et al. Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host & Microbe. 2013; 14: 207-15
22. Gonçalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Current Drug Metabolism. 2013; 14: 994-1008
23. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PloS one. 2009; 4: e6026
24. Neish AS. Microbes in Gastrointestinal Health and Disease. Gastroenterology. 2008; 136: 65-80
25. Wu GD, Compher C, Chen EZ, Smith SA, Shah RD, Bittinger K, et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut. 2016; 65: 63-72
26. Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA and Cell Biology. 2006; 25: 49-62
27. Mathewson ND, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, et al. Gut microbiome derived metabolites modulate intestinal epithelial cell damage and mitigate Graft-versus-Host Disease. Nature Immunology. 2016; 17: 505
28. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. Journal of Applied Bacteriology. 1992; 72: 57-64
29. Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN. Digestion and physiological properties of resistant starch in the human large bowel. British Journal of Nutrition. 1996; 75: 733-47
30. Goncalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Current Drug Metabolism. 2013; 14: 994-1008
31. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Current Opinion in Clinical Nutrition Metabolic Care. 2012; 15: 474-9
32. Wang K, Karin M. Common flora and intestine: A carcinogenic marriage. Cell Logist. 2013; 3: e24975
33. Renaud F, Vincent A, Mariette C, Crepin M, Stechly L, Truant S, et al. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. International Journal of Cancer. 2015; 136: 2811-21
34. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. The Journal of Nutrition. 2009; 139: 1619-25
35. Hatayama H, Iwashita J, Kuwajima A, Abe T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. Biochemical and Biophysical Research Communications. 2007; 356: 599-603
36. Soret R, Chevalier J, De Coppet P, Poupeau G, Derkinderen P, Segain JP, et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology. 2010; 138: 1772-82
37. Hurst NR, Kendig DM, Murthy KS, Grider JR. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterology Motility. 2014; 26: 1586-96
38. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology. 2011; 17: 1519-28
39. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Molecular Cell. 2012; 48: 612-26
40. Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. The Journal of Biological Chemistry. 2008; 283: 12686-90
41. Godman CA, Joshi R, Tierney BR, Greenspan E, Rasmussen TP, Wang HW, et al. HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling. Cancer Biology & Therapy. 2008; 7: 1570-80
42. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors. Experimental Cell Research. 2007; 313: 1652-66
43. Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. Journal of Biomedicine & Biotechnology. 2011; 475641
44. Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015; 20: 3898-941
45. Flores-Perez A, Rincon DG, Ruiz-Garcia E, Echavarria R, Marchat LA, Alvarez-Sanchez E, et al. Angiogenesis Analysis by In Vitro Coculture Assays in Transwell Chambers in Ovarian Cancer. Methods in Molecular Biology (Clifton, NJ). 2018; 1699: 179-86
46. Mahecha AM, Wang H. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and-9 in angiogenesis, metastasis, and prognosis of endometrial cancer. OncoTargets and Therapy. 2017; 10: 4617-24
47. Lan J, Li H, Luo X, Hu J, Wang G. BRG1 promotes VEGF-A expression and angiogenesis in human colorectal cancer cells. Experimental Cell Research. 2017; 360: 236-42
48. Pellizzaro C, Coradini D, Daidone MG. Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis. 2002; 23: 735-40
49. Yu DC, Waby JS, Chirakkal H, Staton CA, Corfe BM. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Molecular Cancer. 2010; 9: 276
50. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunology, Immunotherapy: CII. 2014; 63: 81-99
51. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer letters. 2006; 231: 1-11
52. Staton CA, Koay I, Wu JM, Hoh L, Reed MW, Brown NJ. Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer. Histopathology. 2013; 62: 908-15
53. Ochiumi T, Kitadai Y, Tanaka S, Akagi M, Yoshihara M, Chayama K. Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer. International Journal of Oncology. 2006; 29: 105
54. Wey JS, Gray MJ, Fan F, Belcheva A, Mccarty MF, Stoeltzing O, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. British Journal of Cancer. 2005; 93: 233-41
55. Yu DC, Bury JP, Tiernan J, Waby JS, Staton CA, Corfe BM. Short-chain fatty acid level and field cancerization show opposing associations with enteroendocrine cell number and neuropilin expression in patients with colorectal adenoma. Molecular Cancer. 2011; 10: 27
56. Yu, ChenWei. The effect of butyrate on VEGF and Neuropilin-1 expression in colon cancer. University of Sheffield. 2012
57. Yu DC, Waby JS, Chirakkal H, Staton CA, Corfe BM. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Molecular Cancer. 2010; 9: 276
58. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Experimental Cell Research. 2007; 313: 1285
59. Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010; 56: 180-7
60. Chen LY, Liu X, Wang SL, Qin CY. Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. Journal of International Medical Research. 2010; 38: 498-510
61. Su-Mei, Zhang, Ruo-Lei, Hua-Qing, Qing, Zhou, et al. Correlation between expression and differentiation of endocan in colorectal cancer. World Journal of Gastroenterology. 2008; 14: 4562-8
62. Zuo L, Lu M, Zhou Q, Wei W, Wang Y. Butyrate suppresses proliferation and migration of RKO colon cancer cells though regulating endocan expression by MAPK signaling pathway. Food & Chemical Toxicology. 2013; 62: 892-900
63. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000; 103: 311-20
64. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annual Review of Cell & Developmental Biology. 2003; 14: 59
65. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87: 159-70
66. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000; 103: 311
67. Bordonaro M, Lazarova DL. Butyrate, Wnt Signaling And Colorectal Cancer. 2014
68. Bordonaro M, Lazarova DL, Augenlicht LH, Sartorelli AC. Cell type-and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate. International Journal of Cancer. 2002; 97: 42-51
69. Bordonaro M, Lazarova DL, Sartorelli AC. Butyrate and Wnt signaling: a possible solution to the puzzle of dietary fiber and colon cancer risk? Cell Cycle. 2008; 7: 1178-83
70. Lazarova DL, Bordonaro M, Carbone R, ACS. Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. International Journal of Cancer. 2004; 110: 523-31
71. Lazarova DL, Chiaro C, Bordonaro M. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells. BMC Research Notes. 2014; 7: 226
72. Liu CX, Zhang SZ, Zhang XW, Huang LH, Tie-Jun LI, Zhang J, et al. Sodium butyrate induces apoptosis and regulates p53 target genes in HT-29 colorectal cancer cells. Chinese Journal of Cancer Biotherapy. 2006; 13: 185-90
73. Abaza MSI. Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells. Experimental & Therapeutic Medicine. 2010; 1: 675-93
74. Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Molecular Carcinogenesis. 2013; 52: 459-74
75. Hu S, Dong TS, Dalal SR, Wu F, Bissonnette M, Kwon JH, et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PloS one. 2011; 6: e16221
76. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008; 27: 5959-74
77. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-97
78. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Molecular Cancer. 2009; 8: 102
79. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136: 586-91
80. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annual Review of Medicine. 2009; 60: 167-79
81. Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G, et al. MicroRNA-140-5p inhibits the progression of colorectal cancer by targeting VEGFA. Cell Physiology and Biochemistry. 2015; 37: 1123-33
82. Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiology and Biochemistry. 2015; 35: 499-515
83. Li HT, Zhang H, Chen Y, Liu XF, Qian J. MiR-423-3p enhances cell growth through inhibition of p21Cip1/Waf1 in colorectal cancer. Cell Physiology and Biochemistry. 2015; 37: 1044-54
84. Fang Y, Sun B, Xiang J, Chen Z. MiR-301a promotes colorectal cancer cell growth and invasion by directly targeting SOCS6. Cell Physiology and Biochemistry. 2015; 35: 227-36
85. Fu Q, Zhang J, Xu X, Qian F, Feng K, Ma J. miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5. Tumor Biology. 2016; 37: 1-7
86. Zhang F, Yang Z, Cao M, Xu Y, Li J, Chen X, et al. MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. Cancer letters. 2014; 342: 121-9
87. Abella V, Valladares M, Rodriguez T, Haz M, Blanco M, Tarrio N, et al. miR-203 regulates cell proliferation through its influence on Hakai expression. PloS one. 2012; 7: e52568
88. Tiwari P, Gupta KP. Modulation of miR-203 and its regulators as a function of time during the development of 7, 12 dimethylbenz [a] anthracene induced mouse skin tumors in presence or absence of the antitumor agents. Toxicology and Applied Pharmacology. 2014; 278: 148-58
89. Han R, Sun Q, Wu J, Zheng P, Zhao G. Sodium Butyrate Upregulates miR-203 Expression to Exert Anti-Proliferation Effect on Colorectal Cancer Cells. Cell Physiology and Biochemistry. 2016; 39: 1919-29
90. He L, Thomson JM, Hemann MT, Hernandomonge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435: 828-33
91. Hu S, Liu L, Chang EB, Wang JY, Raufman JP. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Molecular Cancer. 2015; 14: 180
92. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Research. 2004; 64: 3087-95
93. Zhou T, Zhang G, Liu Z, Xia S, Tian H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. International Journal of Colorectal Disease. 2013; 28: 19-24